Acasti Pharma: Plunges after krill oil drug fails trial

Grace Therapeutics

13/01/2020 11:58

** U.S.-listed shares of Canada-based drug developer
 ACST.O  slump 64.7% to 77 cents premarket - set to touch their
lowest level in 9 months
    ** Stock set for its worst day ever 
    ** Co says its investigational krill oil-derived drug,
CaPre, failed to meet the main goal of reducing high levels of
triglycerides after 12 and 26 weeks of treatment in a late-stage
study
    ** Triglycerides are a type of fat found in blood and can
increase the risk of heart disease
    ** Rival Amarin Corp  AMRN.O , which has a similar therapy
Vascepa, is up ~12% at $21.25 premarket
    ** Co says data from secondary goals will be available by
the end of Q1
    ** Also adds that there will be a delay in results from
another trial of CaPre; results now expected by mid-Feb 
    ** Stock down 96.6% in the last 12 months, as of last close 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 0647;))